76 related articles for article (PubMed ID: 2459002)
1. Inhibitory effect of hirudin on thrombosis induced by prothrombin complex concentrates.
Klöcking HP; Schulze-Riewald H; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):106-9. PubMed ID: 2459002
[TBL] [Abstract][Full Text] [Related]
2. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
3. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
Rübsamen K; Hornberger W
Thromb Haemost; 1996 Jul; 76(1):105-10. PubMed ID: 8819261
[TBL] [Abstract][Full Text] [Related]
4. Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis.
Takeyama M; Sakurai Y; Shima M; Matsumoto T; Nogami K; Tanaka I; Takeda T; Giddings JC; Yoshioka A
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):1-7. PubMed ID: 17179819
[TBL] [Abstract][Full Text] [Related]
5. The direct thrombin inhibitor hirudin.
Greinacher A; Warkentin TE
Thromb Haemost; 2008 May; 99(5):819-29. PubMed ID: 18449411
[TBL] [Abstract][Full Text] [Related]
6. Antithrombin is as effective as heparin and hirudin to prevent formation of microvascular thrombosis in a murine model.
Sorg H; Hoffmann JN; Menger MD; Lindenblatt N; Goehring P; Vollmar B
Thromb Haemost; 2006 Sep; 96(3):371-7. PubMed ID: 16953281
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin.
Tapparelli C; Metternich R; Gfeller P; Gafner B; Powling M
Thromb Haemost; 1995 Apr; 73(4):641-7. PubMed ID: 7495072
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
Stassen JM; Lambeir AM; Vreys I; Deckmyn H; Matthyssens G; Nyström A; Vermylen J
Thromb Haemost; 1995 Aug; 74(2):655-9. PubMed ID: 8585002
[TBL] [Abstract][Full Text] [Related]
9. Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models.
Diehl KH; Römisch J; Hein B; Jessel A; Ronneberger H; Pâques EP
Haemostasis; 1995; 25(4):182-92. PubMed ID: 7557657
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
11. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
[TBL] [Abstract][Full Text] [Related]
12. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
McLaughlin LF; Drummond O; MacGregor IR
Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
[TBL] [Abstract][Full Text] [Related]
13. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.
Yasaka M; Sakata T; Naritomi H; Minematsu K
Thromb Res; 2005; 115(6):455-9. PubMed ID: 15792675
[TBL] [Abstract][Full Text] [Related]
14. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial.
van Aart L; Eijkhout HW; Kamphuis JS; Dam M; Schattenkerk ME; Schouten TJ; Ploeger B; Strengers PF
Thromb Res; 2006; 118(3):313-20. PubMed ID: 16182346
[TBL] [Abstract][Full Text] [Related]
15. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
16. Hirudin in the treatment of arterial and venous thrombotic diseases: a new perspective.
Büller HR
Z Kardiol; 1993; 82 Suppl 2():81-2. PubMed ID: 8328213
[TBL] [Abstract][Full Text] [Related]
17. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
Ohyama T; Hori T; Moriike M; Asano T; Hayashi H; Iwade K; Hosoda S
Thromb Haemost; 1998 Feb; 79(2):423-30. PubMed ID: 9493602
[TBL] [Abstract][Full Text] [Related]
18. Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor.
Kaiser B; Markwardt F
Thromb Haemost; 1986 Apr; 55(2):194-6. PubMed ID: 3814237
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin.
Doutremepuich C; Deharo E; Guyot M; Lalanne MC; Walenga J; Fareed J
Thromb Res; 1989 Jun; 54(5):435-45. PubMed ID: 2772867
[TBL] [Abstract][Full Text] [Related]
20. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
Boström SL; Hansson GF; Sarich TC; Wolzt M
Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
